Forkan Ahamed

Mr. Forkan Ahamed


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
XCXiaojuan Chao
Xiaojuan Chao
SWShaogui Wang
Shaogui Wang
SFSam Fulte
Sam Fulte
XMXiaowen Ma
Xiaowen Ma
FAForkan Ahamed
Forkan Ahamed
Wen-Xing DingWen-Xing Ding
Wen-Xing Ding

1 December 2022 in Liver Research
Verified
Journal Article
Open access
NMNancy Magee
Nancy Magee
FAForkan Ahamed
Forkan Ahamed
NENatalie Eppler
Natalie Eppler
EJElizabeth Jones
Elizabeth Jones
PGPriyanka Ghosh
Priyanka Ghosh
Yuxia ZhangYuxia Zhang
Yuxia Zhang
Non-alcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver disease worldwide. The molecular events that influence disease progression from non-alcoholic fatty liver (NAFL) to aggressive non-alcoholic steatohepatitis (NASH) remain incompletely understood, leading to lack of mechanism-based targeted treatment options for NASH. This study aims to identify early signatures associated with disease progression from NAFL to NASH in mice and humans. Male C57BL/6J mice were fed a high-fat, -cholesterol, and - fructose (HFCF) diet for up to 9 months. The extent of steatosis, inflammation, and fibrosis was evaluated in liver tissues. Total RNA sequencing (RNA-seq) was conducted to determine liver transcriptomic changes. After being fed the HFCF diet, mice sequentially developed steatosis, early steatohepatitis, steatohepatitis with fibrosis, and eventually spontaneous liver tumor. Hepatic RNA-seq revealed that the key signatures during steatosis progression to early steatohepatitis were pathways related to extracellular matrix organization and immune responses such as T cell migration, arginine biosynthesis, C-type lectin receptor signaling, and cytokine-cytokine receptor interaction. Genes regulated by transcription factors forkhead box M1 (FOXM1) and negative elongation factor complex member E (NELFE) were significantly altered during disease progression. This phenomenon was also observed in patients with NASH. In summary, we identified early signatures associated with disease progression from NAFL to early NASH in a mouse model that recapitulated key metabolic, histologic, and transcriptomic changes seen in humans. The findings from our study may shed light on the development of novel preventative, diagnostic, and therapeutic strategies for NASH.

13 September 2024 in Livers
Verified
Journal Article
Open access
PDF file
FAForkan Ahamed
Forkan Ahamed
NENatalie Eppler
Natalie Eppler
EJElizabeth Jones
Elizabeth Jones
Yuxia ZhangYuxia Zhang
Yuxia Zhang
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses metabolic dysfunction-associated fatty liver (MASL) and metabolic dysfunction-associated steatohepatitis (MASH), with MASH posing a risk of progression to cirrhosis and hepatocellular carcinoma (HCC). The global prevalence of MASLD is estimated at approximately a quarter of the population, with significant healthcare costs and implications for liver transplantation. The pathogenesis of MASLD involves intrahepatic liver cells, extrahepatic components, and immunological aspects, particularly the involvement of macrophages. Hepatic macrophages are a crucial cellular component of the liver and play important roles in liver function, contributing significantly to tissue homeostasis and swift responses during pathophysiological conditions. Recent advancements in technology have revealed the remarkable heterogeneity and plasticity of hepatic macrophage populations and their activation states in MASLD, challenging traditional classification methods like the M1/M2 paradigm and highlighting the coexistence of harmful and beneficial macrophage phenotypes that are dynamically regulated during MASLD progression. This complexity underscores the importance of considering macrophage heterogeneity in therapeutic targeting strategies, including their distinct ontogeny and functional phenotypes. This review provides an overview of macrophage involvement in MASLD progression, combining traditional paradigms with recent insights from single-cell analysis and spatial dynamics. It also addresses unresolved questions and challenges in this area.

12 December 2019 in Journal of Biological Chemistry
Verified
Journal Article
Closed access
PDF file
NMNancy Magee
Nancy Magee
AZAn Zou
An Zou
PGPriyanka Ghosh
Priyanka Ghosh
FAForkan Ahamed
Forkan Ahamed
DDDon Delker
Don Delker
Yuxia ZhangYuxia Zhang
Yuxia Zhang

4 October 2023 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
PGPriyanka Ghosh
Priyanka Ghosh
NMNancy Magee
Nancy Magee
JAJephte Y Akakpo
Jephte Y Akakpo
FAForkan Ahamed
Forkan Ahamed
NENatalie Eppler
Natalie Eppler
Yuxia ZhangYuxia Zhang
Yuxia Zhang
Acetaminophen (APAP) overdose stands as the primary cause of acute liver failure in the United States. APAP hepatotoxicity involves hepatic glutathione (GSH) depletion and mitochondrial damage. To counteract the toxicity of APAP, the nuclear factor erythroid 2 like 2 (Nrf2) activates the expression of genes responsible for drug detoxification and GSH synthesis. In this study, we present evidence that the elimination of hepatocyte small heterodimer partner (Shp), a critical transcriptional repressor for liver metabolism, results in Nrf2 activation and protects mice from APAP-induced acute liver injury. Initial investigations conducted on wildtype mice revealed a swift downregulation of Shp mRNA within the first 24 hours after APAP administration. Subsequent treatment of hepatocyte-specific Shp knockout (ShpHep-/-) mice with 300 mg/kg APAP for 2 hours exhibited comparable bioactivation of APAP to that observed in the wildtype controls. However, a significant reduction in liver injury was observed in ShpHep-/- after APAP treatment for 6 and 24 hours. The decreased liver injury correlated with a faster recovery of GSH, attributable to heightened expression of Nrf2 target genes involved in APAP detoxification and GSH synthesis. Moreover, in vitro studies revealed that SHP protein interacted with NRF2 protein, inhibiting the transcription of Nrf2 target genes. These findings hold relevance for humans, as overexpression of SHP hindered APAP-induced NRF2 activation in primary human hepatocytes. In conclusion, our studies have unveiled a novel regulatory axis involving SHP and NRF2 in APAP-induced acute liver injury, emphasizing SHP as a promising therapeutic target in APAP overdose induced hepatotoxicity.

21 July 2025 in Livers
Verified
Journal Article
Open access
PDF file
NENatalie Eppler
Natalie Eppler
EJElizabeth Jones
Elizabeth Jones
FAForkan Ahamed
Forkan Ahamed
Yuxia ZhangYuxia Zhang
Yuxia Zhang
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease worldwide, affecting approximately 25–30% of the global adult population and highlighting the urgent need for effective therapeutics and prevention strategies. MASLD is characterized by excessive hepatic lipid accumulation and can progress, in a subset of patients, to metabolic dysfunction-associated steatohepatitis (MASH), a pro-inflammatory and pro-fibrotic condition associated with increased risk of liver cirrhosis and hepatocellular carcinoma. Although the molecular drivers of MASLD progression remain incompletely understood, several key metabolic pathways—such as triglyceride handling, cholesterol catabolism, bile acid metabolism, mitochondrial function, and autophagy—are consistently dysregulated in MASLD livers. This narrative review summarizes primary literature and highlights insights from recent reviews on the multifaceted role of the mRNA-binding protein Human antigen R (HuR) in the post-transcriptional regulation of critical cellular processes, including nutrient metabolism, cell survival, and stress responses. Emerging evidence underscores HuR’s essential role in maintaining liver homeostasis, particularly under metabolic stress conditions characteristic of MASLD, with hepatocyte-specific HuR depletion associated with exacerbated disease severity. Moreover, comorbid conditions such as obesity, type 2 diabetes mellitus, and cardiovascular disease not only exacerbate MASLD progression but also involve HuR dysregulation in extrahepatic tissues, further contributing to liver dysfunction. A deeper understanding of HuR-regulated post-transcriptional networks across metabolic organs may enable the development of targeted therapies aimed at halting or reversing MASLD progression.